First Squawk(@FirstSquawk):Johnson & Johnson Q3 26 Earnings: - Adj EPS: $2.59 (est $2.52) - Sales: $25.40B (est $25.4B) - Medicine Rev: $16.76B (est $16.59B) - Darzalex Rev: $4.24B (est $4.31B) - Tremfya Rev: $2.40B (est $2.21B) - MedTech Sales: $8.64B (est $8.77B) - Sees FY Sales: $101B To $101.4B (est $100.8B To $101.4B) - Sees FY Adj EPS: $11.05 To $11.15 (est $10.96 To $11.11) - Sees FY Adj Oper EPS: $10.95 To $11.05 (est $10.86 To $11.01) - CFO Says Leaning Toward Orthopaedic Unit Spinoff Instead Of Sale

2026.10.13 10:22

Johnson & Johnson Q3 26 Earnings: - Adj EPS: $2.59 (est $2.52) - Sales: $25.40B (est $25.4B) - Medicine Rev: $16.76B (est $16.59B) - Darzalex Rev: $4.24B (est $4.31B) - Tremfya Rev: $2.40B (est $2.21B) - MedTech Sales: $8.64B (est $8.77B) - Sees FY Sales: $101B To $101.4B (est $100.8B To $101.4B) - Sees FY Adj EPS: $11.05 To $11.15 (est $10.96 To $11.11) - Sees FY Adj Oper EPS: $10.95 To $11.05 (est $10.86 To $11.01) - CFO Says Leaning Toward Orthopaedic Unit Spinoff Instead Of Sale